AstraZeneca buys partner Omniose for bacterial vaccine technology
AstraZeneca has acquired preclinical biotechnology company Omniose to strengthen its bacterial vaccine pipeline.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
AstraZeneca has acquired the preclinical biotechnology company Omniose to bolster its vaccine pipeline and incorporate specialized bacterial vaccine technology. According to Business Wire, the acquisition follows a productive three-year exclusive research collaboration between the two companies. Under the terms of the agreement, Omniose is now a wholly owned subsidiary of AstraZeneca and operates as part of the Infectious Disease Unit. Fierce Biotech reported that AstraZeneca bought its partner Omniose for its bacterial vaccine technology.
The acquisition brings Omniose's proprietary bioconjugation platform and expertise into AstraZeneca, supporting its preclinical vaccine programs. Conjugate vaccines are a form of immunization that traditionally require complex chemical processes to attach bacterial polysaccharides to engineered carrier proteins. Business Wire reported that Omniose's bioconjugation approach enables these components to be produced and linked within a single cell, offering a potentially simpler and more precise approach to conjugate vaccine development. The platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within a single E. coli cell.
Christian Harding, CSO and co-founder of Omniose, stated that the milestone reflects the work of exceptional and complementary teams, adding that AstraZeneca has been a trusted partner for several years. Benjamin Moutier, senior vice president of infectious disease at AstraZeneca, stated that the platform represents a differentiated approach to engineering conjugate vaccines and strengthens the company's ability to develop novel vaccines against serious bacterial infections. Timothy Cooke, CEO of Omniose, noted that the organizations share a vision for bringing the best science and talent together to address serious bacterial infections, which are increasingly complicated by antimicrobial resistance according to Business Wire.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
Who acquired Omniose?
AstraZeneca acquired Omniose.
What technology does Omniose use?
Omniose uses a proprietary bioconjugation platform that enables the precise enzymatic attachment of bacterial polysaccharide antigens to engineered carrier proteins within a single E. coli cell.
What unit did Omniose join?
Omniose became part of AstraZeneca's Infectious Disease Unit as a wholly owned subsidiary.
Coverage (5)
- AZ boosts vaccine capabilities with Omniose buy pharmaphorum · 21h ago
- Omniose Announces Its Acquisition by AstraZeneca Business Wire · 21h ago
- AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline Pharmaceutical Executive · 21h ago
- AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition Reuters · 21h ago
- AstraZeneca buys partner Omniose for bacterial vaccine technology Fierce Biotech · 21h ago
Topics
Related trends
CoreWeave Sees ‘No Reason’ That Nvidia Partnership Will Change
CoreWeave maintains absolute confidence in its Nvidia partnership amid a widening industry storm.
EXCLUSIVE: Anthropic eyes $1.4 trillion IPO valuation in test of Wall Street's AI fervor
Anthropic eyes an IPO valuation of up to $1.4 trillion, testing Wall Street's artificial intelligence fervor.
We’ve never seen anything like the Anthropic IPO
Anthropic filed for an IPO seeking a $1.3 trillion valuation, pricing 825 million shares at $70-$78 to raise over $61 billion.
Disney and Adobe are building generative AI tools together
Disney has named Adobe its official AI innovation partner under a multiyear pact to co-develop generative AI tools.
Children’s Place Files for Bankruptcy With Plans to Sell Assets
The Children's Place files for bankruptcy and plans asset sales as loans run dry.
Restaurant 'admin' fees spark backlash as diners question what they're paying for
A diner's viral post showing an unexpected 'admin fee' on a $30.86 restaurant bill has sparked a backlash against hidden surcharges.